Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis

Visit https://www.peervoice.com/JAQ860 to view the entire programme with slides. After completing “Carlo Antozzi, MD - From Helsinki: Expert Perspectives on the Next Generation of Clinical Evidence for FcRn Inhibitors in Myasthenia Gravis”, participants will be able to: Summarise the latest clinical data on emerging FcRn inhibitors in generalised myasthenia gravis (gMG); and Evaluate how emerging evidence is advancing identification of the need for, and optimised management with, FcRn inhibitors in patients with gMG.